Pulmonary arterial hypertension: a look to the future.
暂无分享,去创建一个
[1] M. Gladwin,et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. , 2006, Circulation.
[2] S. Said. Mediators and modulators of pulmonary arterial hypertension. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[3] W. Seeger,et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.
[4] R. Barst,et al. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ILOPROST INHALATION AS ADD-ON THERAPY TO BOSENTAN IN PULMONARY ARTERIAL HYPERTENSION (PAH) , 2005 .
[5] W. Seeger,et al. Imatinib for the treatment of pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[6] D. Stewart,et al. Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow–Derived Endothelial-Like Progenitor Cells: Efficacy of Combined Cell and eNOS Gene Therapy in Established Disease , 2005, Circulation research.
[7] J. Yuan,et al. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. , 2005, Circulation.
[8] K. Kangawa,et al. Adrenomedullin in the treatment of pulmonary hypertension , 2004, Peptides.
[9] J. Dötsch,et al. Brief adrenomedullin inhalation leads to sustained reduction of pulmonary artery pressure , 2004, European Respiratory Journal.
[10] K. Kaibuchi,et al. Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats , 2004, Circulation research.
[11] G. Berry,et al. Simvastatin Rescues Rats From Fatal Pulmonary Hypertension by Inducing Apoptosis of Neointimal Smooth Muscle Cells , 2003, Circulation.
[12] G. Funk,et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. , 2003, The Journal of clinical investigation.
[13] P. Thistlethwaite,et al. Signaling molecules in nonfamilial pulmonary hypertension. , 2003, The New England journal of medicine.
[14] G. Berry,et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. , 2002, American journal of respiratory and critical care medicine.
[15] J. Yuan,et al. Ion channels in pulmonary arterial hypertension. , 2002, Progress in cardiovascular diseases.
[16] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[17] M. Humbert,et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.
[18] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[19] M. Humbert,et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.
[20] L. Rubin,et al. Augmented K(+) currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis. , 2001, American journal of physiology. Lung cellular and molecular physiology.
[21] K. Kangawa,et al. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension , 2000, Heart.
[22] M. Humbert,et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family , 2000, Journal of medical genetics.
[23] S. Hodge,et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.
[24] R. Trembath,et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.
[25] C. Indolfi,et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. , 2000, Journal of the American College of Cardiology.
[26] D. Badesch,et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.
[27] J. Orens,et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. , 1998, Circulation.
[28] B. Fanburg,et al. A new role for an old molecule: serotonin as a mitogen. , 1997, The American journal of physiology.
[29] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[30] B. Groves,et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.